Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig’s Disease (ALS)

Adeona Pharmaceuticals has stepped into the ALS space, announcing a planned Phase IIb clinical trial to evaluate the safety and efficacy of two potential therapies (a zinc-based tablet and a copper tablet) in ALS patients. The trial is to be conducted by the neurology team at the PNA Center for Neurological Research in collaboration with The Institute for EthnoMedicine.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail